Gastroenterology
Volume 130, Issue 7 , Pages 2031-2038 , June 2006

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd–Chiari Syndrome

  • Raj K. Patel

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
    • Corresponding Author InformationAddress requests for reprints to: Raj K. Patel, MD, Department of Haematological Medicine, King’s College Hospital, Denmark Hill, London, SE5 9RS England. fax: (44) 20-7346-4689
    • Dr Patel and Dr Lea contributed equally to this study.
    • ,
  • Nicholas C. Lea

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
    • Dr Patel and Dr Lea contributed equally to this study.
    • ,
  • Michael A. Heneghan

      Affiliations

    • Institute of Liver Studies, King’s College Hospital, London, England
    • ,
  • Nigel B. Westwood

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
    • ,
  • Dragana Milojkovic

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
    • ,
  • Murugaiyan Thanigaikumar

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
    • ,
  • Deborah Yallop

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
    • ,
  • Roopen Arya

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
    • ,
  • Antonio Pagliuca

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
    • ,
  • Joop Gäken

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom
    • ,
  • Julia Wendon

      Affiliations

    • Institute of Liver Studies, King’s College Hospital, London, England
    • ,
  • Nigel D. Heaton

      Affiliations

    • Institute of Liver Studies, King’s College Hospital, London, England
    • ,
  • Ghulam J. Mufti

      Affiliations

    • Department of Haematological Medicine, King’s College Hospital, London, United Kingdom

Received 8 March 2005 ,Accepted 16 January 2006.

References 

  1. Ludwig J, Hashimoto E, McGill DB, et al. Classification of hepatic venous outflow obstruction (ambiguous terminology of the Budd–Chiari syndrome). Mayo Clin Proc. 1990;65:51–55
  2. Hadengue A, Poliquin M, Vilgrain V, et al. The changing scene of hepatic vein thrombosis (recognition of asymptomatic cases). Gastroenterology. 1994;106:1042–1047
  3. Bismuth H, Sherlock DJ. Portosystemic shunting versus liver transplantation for the Budd–Chiari syndrome. Ann Surg. 1991;214:581–589
  4. Narayanan Menen KV, Shah V, Kamath P. The Budd–Chiari Syndrome. N Engl J Med. 2004;350:578–585
  5. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic vein thrombosis in adults (the role of multiple concurrent factors). Hepatology. 2000;31:587–591
  6. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis (a prospective study of erythroid colony formation in vitro in 20 patients with Budd–Chiari Syndrome). Ann Intern Med. 1985;103:329–334
  7. Primignani M, Martinelli I, Bucciarelli P. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41:603–608
  8. Wasserman L. The management of Polycythemia Vera. Br J Haematol. 1971;21:371–376
  9. Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol. 2001;38(Suppl 2):21–24
  10. Vardiman JW, Harris NL, Brunnung RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  11. Murphy S. Therapeutic dilemmas (balancing the risks of bleeding, thrombosis and leukemic transformation in myeloproliferative disorders (MPD)). Thromb Haemost. 1997;78:622–626
  12. Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis—possible evidence of an occult myeloproliferative state. Q J Med. 1990;76:981–989
  13. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd–Chiari syndrome. Ann Intern Med. 1985;103:329–334
  14. Valla D, Casadevall N, Huisse MG, et al. Aetiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94:1063–1069
  15. Muller EW, De Wolf JT, Haagsma EB. Portal hypertension as a presenting feature of a myeloproliferative disorder. Diagnosis and therapeutic dilemmas. Scand J Gastroenterol Suppl. 1993;200:74–79
  16. De Stefano V, Teofili L, Leone G, et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd–Chiari syndrome or portal vein thrombosis. Semin Thromb Haemost. 1997;23:411–418
  17. McNamara C, Juneja S, Wolf M, et al. Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts. Clin Lab Hematol. 2002;24:239–242
  18. Dudley JM, Westwood N, Leonard S, et al. Primary polycythemia (positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon). Br J Haematol. 1990;75:188–194
  19. Dainiak N, Hoffman R, Lebowitz AI, et al. Erythropoietin-dependent primary pure erythrocytosis. Blood. 1979;53:1076–1084
  20. Eridani S, Dudley JM, Sawyer BM, et al. Erythropoietic colonies in a serum-free system (results in primary proliferative polycythemia and thrombocythemias). Br J Haematol. 1987;67:387–391
  21. Lemoine F, Najman A, Baillou C, et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood. 1986;68:996–1002
  22. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders (it all makes sense). Blood. 2005;105:4258–4263
  23. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet. 2005;365:1054–1061
  24. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397
  25. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144–1148
  26. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790
  27. Westwood NB, Gruszka-Westwood AM, Atkinson S, et al. Polycythemia vera (analysis of DNA from blood granulocytes using comparative genomic hybridisation). Haematologica. 2001;86:464–469
  28. Westwood NB, Pearson TC. Diagnostic applications of haemopoietic progenitor culture techniques in polycythemias and thrombocythemias. Leukemia Lymphoma. 1996;22(Suppl 1):95–103
  29. Acharya J, Westwood NB, Sawyer BM, et al. Identification of latent myeloproliferative disease in patients with Budd–Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol. 1995;55:315–321
  30. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556–562
  31. Pearson TC, Botterill CA, Glass UH, et al. Interpretation of measured red cell mass and plasma volume in males with elevated venous PCV values. Scand J Haematol. 1984;33:68–74
  32. Wolanskyi AP, Lasho TI, Schwager SM, et al. JAK2V617F mutation in essential thrombocythemia (clinical associations and long-term prognostic relevance). Br J Haematol. 2005;131:208–213
  33. Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd–Chiari syndrome (a multivariate analysis of factors related to survival including portosystemic shunting). Hepatology. 1999;30:84–89
  34. Srinivasan P, Rela M, Prachalias A, et al. Liver transplantation for the Budd–Chiari syndrome. Transplantation. 2002;73:973–977
  35. Melear JM, Goldstein RM, Levy MF, et al. Hematologic aspects of liver transplantation for Budd–Chiari syndrome with special reference to myeloproliferative disorders. Transplantation. 2002;74:1090–1095

PII: S0016-5085(06)00745-1

doi: 10.1053/j.gastro.2006.04.008

Gastroenterology
Volume 130, Issue 7 , Pages 2031-2038 , June 2006

Article Tools

* Image Usage & Resolution